--- title: "NHS National Pharmaceuticals Transition 2021_3" ocid: "ocds-h6vhtk-02b7a6" canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02b7a6" markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-02b7a6.md" json_url: "https://d3tenders.com/contract/ocds-h6vhtk-02b7a6.json" source: "Find A Tender Service" current_stage: "Award" buyer: "THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND)" published: "2021-11-04" --- # NHS National Pharmaceuticals Transition 2021_3 Buyer: THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND) Current stage: Award OCID: ocds-h6vhtk-02b7a6 [View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02b7a6) [Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-02b7a6.json) ## Summary The NHS Commissioning Board (operating under the name of NHS England) is currently conducting an open tender for the NHS National Pharmaceuticals Transition 2021_3. This procurement, classified under the pharmaceutical products category, is set in the UK and is aimed at supplying goods valued at approximately £214 million. The tender consists of several lots including oral products for all regions, hospital-only products for various regions (LSNE, NWLN, CESW), and transition products. Key dates are crucial, with the tender period concluding on 7th July 2021 and contract periods spanning from October 2021 through various endings depending on the lot. The contract may have options for extensions of up to 48 months at the discretion of the authority. This procurement process offers significant opportunities for businesses engaged in pharmaceutical manufacturing and supply. Companies specialising in hospital products, oral pharmaceuticals, and related healthcare services can compete effectively for this contract. Established and emerging suppliers aiming to expand their footprint within public health sectors should consider participating, particularly as the framework agreement allows for a potentially expansive scope of business across multiple NHS bodies and local authorities. Interested parties should ensure compliance with the procurement requirements and be well-prepared for submission through the designated eTendering portal. ## Notice NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633 ### Lot Information Hospital Only Products - CESW region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products:LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition:LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Options: option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months. Hospital Only Products - LSNE region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents Options: option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months. Hospital Only Products - NWLN region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Options: option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months. Oral (plus non-parenteral) products: All regions NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Options: option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months. Transition Products - CESW region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Options: option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months. Transition Products - LSNE region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Options: option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months. Transition Products - NWLN region NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Options: option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months. ## Key Details | Field | Value | | --- | --- | | Publication source | Find A Tender Service | | Latest notice | https://www.find-tender.service.gov.uk/Notice/027695-2021 | | Notice type | Tender Notice | | Procurement type | Framework | | Procurement category | Goods | | Procurement method | Open | | Procurement method details | Open procedure | | Tender suitability | Not specified | | Awardee scale | Large, SME | | All stages | Tender, Award | ## Dates | Field | Value | | --- | --- | | Publication date | 4 Nov 2021 | | Submission deadline | 7 Jul 2021 | | Future notice date | Not specified | | Award date | 13 Sep 2021 | | Contract period | 25 Oct 2021 - 30 Sep 2023 | | Recurrence | Not specified | ## Values | Field | Value | | --- | --- | | Tender value | £214,113,004 | | Lots value | Not specified | | Awards value | Not specified | | Contracts value | £1 | ## Status | Field | Value | | --- | --- | | Tender status | Complete | | Lots status | Cancelled | | Awards status | Active | | Contracts status | Active | ## Buyer | Field | Value | | --- | --- | | Main buyer | THE NHS COMMISSIONING BOARD (OPERATING UNDER THE NAME OF NHS ENGLAND) | | Locality | RUNCORN | | Post town | Warrington | | Postcode | WA7 2ES | | Country | England | | ITL 1 | TLD North West (England) | | ITL 2 | TLD7 Merseyside | | ITL 3 | TLD71 East Merseyside | | Local authority | Halton | | Electoral ward | Halton Lea | | Westminster constituency | Runcorn and Helsby | | Delivery location | Not specified | ## Supplier | Field | Value | | --- | --- | | Number of suppliers | 36 | | Supplier names | ACCORD-UK; AGUETTANT; ALTURIX; AMAROX; AMBE MEDICAL GROUP; ASPEN PHARMACARE; ASPIRE PHARMA; BROWN AND BURK; CIPLA (EU; COLONIS PHARMA; CONSILIENT HEALTH; CST PHARMA; DAY LEWIS MEDICAL; DR.REDDY'S LABORATORIES (UK; DRUGSRUS; GLENMARK PHARMACEUTICALS EUROPE; KENSINGTON PHARMA; KENT PHARMA; LABORATORIO REIG JOFRE; LUCANE PHARMA; MACURE PHARMA; MEDAC PHARMA; MERCURY PHARMACEUTICALS; MORNINGSIDE PHARMAEUTICALS; MYLAN; NAPP PHARMACEUTICALS; PANPHARMA; PFIZER; RANBAXY; ROCHE PRODUCTS; SEACROSS PHARMACEUTICALS; TEVA; THORNTON AND ROSS; TORBAY PHARMACEUTICALS; WOCKHARDT; ZENTIVA PHARMA | ## CPV Codes ### Divisions - 33 - Medical equipments, pharmaceuticals and personal care products ### Codes - 33600000 - Pharmaceutical products ## Release History - 4 Nov 2021 at 14:00 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/027695-2021 - 2 Jun 2021 at 15:02 - Tender - Tender Notice - https://www.find-tender.service.gov.uk/Notice/012340-2021 ## Notice URLs - http://health.atamis.co.uk - http://health.atamis.co.ukCandidates - https://supplierregistration.cabinetoffice.gov.ukand - https://www.england.nhs.uk/ - https://www.gov.uk/courts-tribunals ## Provenance This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-02b7a6. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-02b7a6.json.